Latham & Watkins Advises on Vir Biotechnology’s US$150 Million Public Offering of Common Stock

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, has announced the pricing of its underwritten public offering of 17,647,058 shares of its common stock at a price to the public of US$8.50 per share. The gross proceeds to Vir Biotechnology from the offering are expected to be US$150 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Vir Biotechnology has granted the underwriters a 30-day option to purchase up to an additional 2,647,058 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are being sold by Vir Biotechnology. Closing of the offering is expected to occur on February 27, 2026, subject to customary closing conditions.

Latham & Watkins LLP represents the underwriters in the transaction with a Capital Markets team led by Orange County partners Shayne Kennedy and Drew Capurro, with associates Gregory Van Buiten, Kennedy Holmes, and Ariana Alemi. Advice was also provided on healthcare matters by Bay Area partner Betty Pang; on FDA matters by San Diego counsel Amy Speros, with associate Hannah Chi; on intellectual property matters by San Diego counsel Robert Yeh, with associate Kristina Funahashi; on data privacy and cybersecurity matters by San Francisco partner Heather Deixler, with associate Alexandra Gómez; and on tax matters by Bay Area partner Grace M. Lee, with associate Dennis Poehland.